RespireRx Pharmaceuticals Inc (fka RSPI)

[gfp927z]

Neuro, "There is no dosing restriction". But that only applies to the PET study. We haven't received any assurances from Neurology that higher dosing will be allowed for longer trials.

When Neurology has completed their review of the tox data, just wondering if you see another separate Cortex press release coming prior to the IND press release, something stating that Neurology has completed their evaluation of the tox data and have officially lifted all dosing restrictions on CX-717? Thanks.